Baltimore, MD, 19 March 2010. - New research has revealed a major breakthrough in the use of cough medicine ingredient noscapine as a prophylactic treatment for prostate cancer.
The study shows that noscapine inhibited tumor growth in mice and also limited the spread of tumors without causing any side effects.
The collaborative pre-clinical laboratory research was conducted by Dr. Israel Barken, of the Prostate Cancer Research and Education Foundation (PCREF), Moshe Rogosnitzky, of the MedInsight Research Institute and Dr. Jack Geller, of the University of California San Diego.
They concluded that noscapine administered as a preventive measure may offer significant benefits in the management of prostate cancer, a disease that kills more than 28,000 men in the U.S. each year.
Their findings said: "Pre-treatment with noscapine confers a significant benefit compared with control in both primary tumor growth and primary tumor growth- inhibition rate and exhibits an extremely favorable tolerability profile."
The research team is now keen to take their work further by examining the effects of noscapine - a non-addictive derivative of opium - as a prophylactic agent given to patients following prostate cancer surgery or radiation.
Dr. Barken, Founder and Medical Director of the PCREF in San Diego, California, said: "PCREF is now seeking sponsorship for clinical data collection in post-surgery patients who are at high-risk of recurrence for their prostate cancer.
"Based on our research so far, we believe that noscapine could be a very promising treatment to prevent recurrence in such cases due to its excellent safety record and oral bioavailability."
The latest research focused on pre-treating mice with noscapine before injecting them with prostate cancer cells. This resulted in the tumor growth rate being two-thirds smaller in the noscapine group compared with a non-noscapine group.
The study also found that lung metastasis rates were 80% less in the mice pre-treated with noscapine, while the experts noted that the noscapine group suffered no cancer-related weight loss - compared with significant weight loss in the non-noscapine group.
Noscapine has been used worldwide since the 1950s as an ingredient in over-the-counter cough medicines and was originally suggested as an anti-cancer agent in the early 1960s. But major studies of its anti-cancer properties have only taken place in recent years.
The latest research is the result of ongoing collaborative work between the Prostate Cancer Research and Educational Foundation (PC-REF) and Baltimore-based MedInsight Research Institute. Their previous work has shown that noscapine has properties that limit the growth of prostate cancer.
The latest study was based on the theory that prostate cancer could be a suitable target for a risk-reduction approach because of its high prevalence and significant morbidity and mortality.
Moshe Rogosnitzky, co-founder and Director of Research at the MedInsight Research Institute, said: "There is an ever-growing need for effective ways to prevent recurrence of cancer after curative surgery.
"It is MedInsight's belief that many effective treatments for this and other diseases can be selected from the vast armory of existing off-patent and unpromoted drugs. The results of this study, once confirmed in a clinical trial, are an example where we may yet again have an agent that not only has an envious safety record, but is already available for use today."
The findings of the pre-clinical study are published in Anticancer Research (Volume 30:2, 2010, pp. 399-402) on March 19 2010.
About Prostate Cancer Research and Educational Foundation (PC-REF)
PC-REF, a 501(c)(3) non-profit public foundation based in San Diego, California. It was founded by Dr. Israel Barken in 1997. PC-REF focuses on patient coaching and education, and provides financial support for innovative prostate cancer research projects. Its focus is on research ideas that can benefit today's patients. PC-REF's web site is www.pcref.org.
About MedInsight® Research Institute
MedInsight® Research Institute is committed to bringing relief to those who suffer from cancer or chronic medical conditions by making doctors aware of commercially unsponsored medications, off-label uses for approved medicines, long-lost therapies and specialized tests that enable treatment to be tailored to the individual. As a U.S.-based 501(c)(3) non-profit organization, MedInsight works to bridge the widening gap between medical research and medical practice. www.medinsight.org